The efforts of the Biden administration to accelerate rollout of COVID-19 vaccines are enabling more adults in the US to be vaccinated each week. As of February 28, 2021, an estimated more than 48 million people have received at least 1 vaccine dose. Provided enough people are vaccinated, the US might be able to transition back toward prepandemic life at some point this year. However, one scenario that could adversely affect the vaccine program is the further evolution and spread of viral variants that are resistant to vaccine-induced neutralizing antibodies. It is prudent to discuss possible strategies to minimize the potential effects of this problem, and other scenarios for maximizing the benefit of available and future vaccine supplies.
Moore JP. Approaches for Optimal Use of Different COVID-19 Vaccines: Issues of Viral Variants and Vaccine Efficacy. JAMA. 2021;325(13):1251–1252. doi:10.1001/jama.2021.3465
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.